文献速递淋巴瘤

EBV状态与组织学对纳武利尤单抗-AVD vs BV-AVD治疗晚期经典型霍奇金淋巴瘤疗效的影响(S1826研究)

Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826).
PubMed 文献 · Blood Adv · 2026-01-01

该研究为3期SWOG S1826试验的预设亚组分析,评估EBV状态和组织学亚型对N-AVD或BV-AVD治疗晚期cHL患者结局的影响。结果显示N-AVD在EBV+和非结节硬化型亚组中显著改善3年PFS,且非结节硬化型是不良预后独立因素,但N-AVD仍在该高风险组中显示有利PFS。

核心结论

  • N-AVD大幅削弱了晚期cHL中EBV+状态和非结节硬化型组织学 historically 相关的不良预后,支持N-AVD作为一线标准治疗,尤其在高风险生物学亚组。

研究设计与样本

  • 3期SWOG S1826试验的预设亚组分析,纳入970例可评估的III-IV期cHL患者,随机接受N-AVD或BV-AVD治疗。
  • 522例已知EBV状态,664例有切片可供组织学回顾,其中102例(15.4%)为非结节硬化型。

临床怎么用

  • N-AVD应作为晚期cHL一线标准治疗,尤其对EBV+或非结节硬化型等高风险生物学亚组。
  • BV-AVD治疗时,EBV+或非结节硬化型患者PFS显著更差,需考虑更有效方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Classic Hodgkin lymphoma (cHL) associated with Epstein-Barr virus (EBV) positive status as well as nonnodular sclerosis (non-NS) histologic subtypes has demonstrated poorer outcomes compared with EBV- and NS tumors. We report a prespecified subset analysis of patients enrolled in the phase 3 SWOG S1826 trial to evaluate outcomes based on EBV status and histologic subtype in patients treated with N-AVD (nivolumab-AVD) or BV-AVD (brentuximab vedotin-AVD). In the phase 3 SWOG S1826 trial, patients with stage III to IV cHL were randomized to N-AVD or BV-AVD treatment. Of 970 eligible patients, 522 had known EBV status. N-AVD improved 3-year progression-free survival (PFS) in patients who were EBV+ (91% vs 70%; hazard ratio [HR], 0.30; P = .01) and EBV- (90% vs 84%; HR, 0.64; P = .09). Among 664 patients with slides available for histology review, 102 (15.4%) had non-NS histologic subtypes. N-AVD prolonged 3-year PFS in patients with non-NS histologic subtype (86% vs 63%; HR, 0.33; P = .006) and NS histologic subtype (93% vs 86%; HR, 0.53; P = .01). Non-NS histologic subtype was independently associated with inferior outcomes (HR, 2.54; P< .0001) after adjusting for treatment in the entire cohort. However, N-AVD treatment still had favorable PFS within this high-risk group. In addition, patients with EBV+ status or non-NS histologic subtype cHL treated with BV-AVD had significantly worse PFS (HR, 1.97; P = .03 for EBV and HR, 3.08; P< .0001 for histology). N-AVD substantially abrogated the historically poor prognosis associated with EBV+ status and non-NS histologic subtype in advanced-stage cHL. These results support N-AVD as a frontline standard of care, particularly in high-risk biologic subgroups. This trial was registered at www.clinicaltrials.gov as NCT03907488.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ahmed S, Li H, Herrera AF, et al. Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826). Blood Adv. 2026. PMID: 42526889. doi:10.1182/bloodadvances.2026021402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。